Ethical issues raised by genetic testing with oligonucleotide microarrays

被引:13
作者
Grody, WW
机构
[1] Univ Calif Los Angeles, Sch Med, Div Med Genet, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Sch Med, Div Mol Pathol, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA
[4] Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA
[5] Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90024 USA
关键词
microarray; DNA chip; molecular genetic testing; ethics; eugenics; discrimination;
D O I
10.1385/MB:23:2:127
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Because genes and alterations within them determine the identity, characteristics, and inheritance of every individual, the application of genetic science to humans has long been surrounded by apprehension, controversy, and real or perceived potential for abuse. Crude eugenics practices of the past now find a theoretical rebirth and transformation through the use of modem molecular genetic technologies for mutation detection, predictive and prenatal diagnosis, and, ultimately, gene replacement. The advent of oligonucleotide microarray analysis, in which hundreds or thousands of genes and mutations can be tested in parallel, offers tremendous promise for more accurate, sensitive, and efficient genetic testing. At the same time, however, this powerful technology dramatically increases the number and scope of ethical concerns accompanying each individual test request. This article considers the evolution and implications of these concerns, from the initial ordering of a microarray test by the physician to such issues as informed consent, privacy, confidentiality, clinical utility, discrimination, stigmatization, ethnic and population impact, and reimbursement.
引用
收藏
页码:127 / 138
页数:12
相关论文
共 38 条
[31]  
Peterson EA, 2002, CANCER EPIDEM BIOMAR, V11, P79
[32]   Rethinking risks to human subjects in genetic research [J].
Reilly, PR .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (03) :682-685
[33]   BRCA 1 sequence analysis in women at high risk for susceptibility mutations - Risk factor analysis and implications for genetic testing [J].
ShattuckEidens, D ;
Oliphant, A ;
McClure, M ;
McBride, C ;
Gupte, J ;
Rubano, T ;
Pruss, D ;
Tavtigian, SV ;
Teng, DHF ;
Adey, N ;
Staebell, M ;
Gumpper, K ;
Lundstrom, R ;
Hulick, M ;
Kelly, M ;
Holmen, J ;
Lingenfelter, B ;
Manley, S ;
Fujimura, F ;
Luce, M ;
Ward, B ;
CannonAlbright, L ;
Steele, L ;
Offit, K ;
Gilewski, T ;
Norton, L ;
Brown, K ;
Schulz, C ;
Hampel, H ;
Schluger, A ;
Giulotto, E ;
Zoli, W ;
Ravaioli, A ;
Nevanlinna, H ;
Pyrhonen, S ;
Rowley, P ;
Loader, S ;
Osborne, MP ;
Daly, M ;
Tepler, I ;
Weinstein, PL ;
Scalia, JL ;
Michaelson, R ;
Scott, RJ ;
Radice, P ;
Pierotti, MA ;
Garber, JE ;
Isaacs, C ;
Peshkin, B ;
Lippman, ME .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (15) :1242-1250
[34]  
Strass E, 1996, AM J HUM GENET, V59, P471
[35]   THE CARRIER FREQUENCY OF THE BRCA1 185DELAG MUTATION IS APPROXIMATELY 1 PERCENT IN ASHKENAZI-JEWISH INDIVIDUALS [J].
STRUEWING, JP ;
ABELIOVICH, D ;
PERETZ, T ;
AVISHAI, N ;
KABACK, MM ;
COLLINS, FS ;
BRODY, LC .
NATURE GENETICS, 1995, 11 (02) :198-200
[36]  
*TASK FORC GEN TES, 1998, PROM SAF EFF GEN TES
[37]  
U. S. Dep't of Justice & FTC, 1997, HUM GEN PROGR REP 1, P18
[38]   Finding a workable balance - Regulation of genetic testing in the human genome era [J].
Voelkerding, KV .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2000, 2 (02) :57-59